A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Recruiting
Phase 1
Interventional Study
PROC
Platinum Resistant Ovarian Cancer
Endometrial Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 265 (estimated)
- Sponsor
- Whitehawk Therapeutics, Inc. · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
HWK-016-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-016, a targeted antibody-drug conjugate (ADC) in adult participants with advanced or metastatic solid tumors. The study employs a dose escalation and dose expansion design without a control group.
The study consists of 2 parts (Part A: monotherapy and Part B: combination therapy with bevacizumab); each par…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Have one of the following solid tumor cancers:
1. Monotherapy escalation, backfill and expansion cohorts:
1. Endometrial Carcinoma
2. Ovarian Cancer
2. Combination Escalation, Backfill and Expansion Cohorts a. Ovarian Cancer
Exclusion Criteria:
1. Individual …
Contacts